In a significant move for the tech landscape, Galatek, a pioneering startup based in Singapore, has announced that it has successfully raised approximately $30 million in Series A funding. This strategic infusion of capital aims to accelerate the development of innovative artificial intelligence (AI) and automation solutions specifically tailored for the life sciences and semiconductor manufacturing sectors. As the demand for intelligent automation solutions continues to rise, Galatek positions itself at the forefront of this transformation by strengthening its global supply chain and enhancing local expertise across key markets.

Founded in Singapore’s vibrant innovation hub, Galatek is addressing some of the most critical challenges facing industries today. Through its advanced automation and AI solutions, the company is reshaping smart laboratory environments and advancing semiconductor packaging techniques, two vital sectors that rely heavily on precision and intelligent design. The startup’s approach combines agile research and development capabilities with localized commercial efforts, establishing itself as a key player in the rapidly evolving AI landscape.

Galatek’s focus is strategically placed on two high-demand market areas: life sciences and semiconductors. In the realm of life sciences, Galatek is leading the charge toward the smart laboratory of the future. By deeply integrating AI into research and development workflows, the company aims to empower scientists to significantly accelerate and de-risk discovery across a variety of complex applications. These applications include diagnostics, next-generation sequencing, 3D cell and organoid culture, drug development, and synthetic biology.

One of the standout offerings from Galatek is its Abio software platform, an integrated, AI-driven solution that unifies electronic laboratory notebooks (ELN), laboratory information management systems (LIMS), scientific data management systems (SDMS), and advanced automation. This comprehensive platform transforms scientific data into actionable insights, streamlining robotic integrations and supporting customizable, cloud-agnostic operations within smart labs. Furthermore, Galatek has established strategic partnerships with leading global pharmaceutical companies and prestigious research institutions, including collaborations with the National University of Singapore, enhancing its capability to co-create next-generation smart laboratories.

In the semiconductors sector, Galatek’s commitment to AI-driven innovation is evident through its focus on advanced packaging. The company integrates vision AI and motion control algorithms to meet the rigorous demands for precision and reliability in semiconductor processes. Galatek provides a range of essential process equipment and solutions, from front-end metrology and inspection to back-end advanced packaging. Some of its core offerings include fully automated overlay measurement systems, deep learning-based automatic optical inspection (AOI) systems, and precision wafer dicing equipment. The startup is also collaborating with several leading global semiconductor manufacturers, showcasing its capabilities from technological breakthroughs to commercial scale delivery.

Galatek operates under a unique business model described as “Global Supply Chain + Localized Service,” which effectively combines competitive advantages from both local and international operations. This model not only amplifies Galatek’s operational efficiency but also enhances its ability to deliver tailored solutions to meet the needs of its diverse client base across various regions.

As the landscape of AI and automation technology evolves, Galatek exemplifies the drive to innovate within sectors that are critical to future advancements in science and technology. The company’s successful funding round will bolster its mission to revolutionize the life sciences and semiconductor industries by providing cutting-edge automation and AI solutions that are essential for advancing research, speeding up production processes, and ultimately facilitating remarkable discoveries.